GET DAILY SIGNALSFocalTherics (FOCL) Posts +26% HIFU Revenue Growth in Q3 2026
Key Takeaways
- Third Quarter 2026 HIFU revenue reached $9.8 million, up 26% from $7.8 million a year earlier.
- Gross margin improved to 51.4% from 46.6%, a gain of 482 basis points.
- Net loss narrowed to $4.5 million, or $0.10 per share, from $5.9 million, or $0.16 per share, in the prior-year quarter.
- Seven Focal One system sales were recorded in the quarter versus six a year earlier, while U.S. procedure volumes rose 32%.
- Cash and cash equivalents climbed to $56.3 million, lifted by the company's August equity raise.
- Full-year 2026 revenue guidance was narrowed to $50 million–$52 million, from a prior range of $50 million–$54 million.
Earnings Context and Why It Matters
FocalTherics (formerly EDAP TMS) is repositioning itself as a pure-play leader in robotic focal therapy for prostate cancer through its Focal One HIFU platform. This quarter marks its second report under a revised structure in which the HIFU business is presented as continuing operations, while its ESWL and Distribution segments are classified as discontinued operations. For investors, the Q3 2026 print offers a clean look at the growth, margin trajectory, and cash needs of the core franchise that now defines the company's long-term thesis. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter of 2026, ended September 30, 2026, FocalTherics reported HIFU segment revenue of $9.8 million, a 26% increase from $7.8 million in the year-ago period. The gain was driven by seven Focal One system sales, up from six a year earlier, along with a 24% rise in treatment-driven revenue. U.S. Focal One procedure volumes grew 32% year over year.
Gross margin expanded to 51.4% from 46.6%, reflecting improved standard costs and higher average selling prices on systems and FocalPaks. Operating expenses rose to $12.8 million from $10.3 million, pushing the operating loss to $7.8 million versus $6.7 million a year earlier. Net loss, however, narrowed to $4.5 million, or $0.10 per share, compared with $5.9 million, or $0.16 per share, helped by a $2.6 million non-cash gain from a change in the fair value of European Investment Bank warrants and $0.5 million in foreign-exchange gains.
Management narrowed full-year 2026 revenue guidance to $50 million–$52 million, representing 34%–39% growth, from the prior $50 million–$54 million range, citing three U.S. capital system sales that slipped from Q3 into Q4.
Market Reaction and Investor Sentiment
Investor sentiment around the quarter is likely to be shaped by two competing signals. On the positive side, the company demonstrated durable double-digit growth in procedures and recurring treatment revenue, margin expansion, and a much stronger cash position following its equity raise. On the other hand, the deferral of three U.S. capital system sales into the fourth quarter and the corresponding tightening of annual guidance underscore the quarter-to-quarter lumpiness inherent in hospital capital-equipment purchasing. Management attributed the timing shift to value-analysis committee reviews and financing delays rather than a loss of demand, and noted that one deferred sale has already closed. Investors will be weighing the strength of the underlying procedure momentum against the near-term visibility challenges in system placements.
Forward Outlook and Key Factors to Monitor
Looking ahead, the fourth quarter will be the key test of management's updated outlook. The company has said it expects to close the deferred U.S. system sales, which should support a seasonally stronger finish to the year. Investors will want to see confirmation that full-year revenue lands within the narrowed $50 million–$52 million range and that gross margin gains are sustained.
Beyond the quarter, several catalysts deserve attention. The company continues to advance its BPH and endometriosis programs from early clinical studies toward broader adoption, which could expand its addressable market beyond prostate cancer. A proposed increase in the CMS facility payment for HIFU procedures could further support hospital economics and reimbursement. Finally, watch procedure volume growth and the pace of new account additions, as rising utilization of the installed base underpins recurring, higher-margin treatment revenue. From what I see, this is important because it points to the sustainability of the core business model.
Using AI Tools for Deeper Analysis
In my view, tools like Tickeron’s AI Daily Buy/Sell Signals can help track momentum in names like FOCL alongside broader market patterns. I find it useful to cross-reference earnings data with AI-driven signals to get a clearer picture of potential entry or exit points without relying solely on manual review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
FOCL's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for FOCL turned positive on October 21, 2026. Looking at past instances where FOCL's MACD turned positive, the stock continued to rise in 36 of 41 cases over the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 43 of 56 cases where FOCL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
FOCL moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where FOCL advanced for three days, in 185 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FOCL as a result. In 74 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The 50-day moving average for FOCL moved below the 200-day moving average on October 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FOCL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for FOCL entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. FOCL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-61.199) is normal, around the industry mean (13.339). P/E Ratio (-4.019) is within average values for comparable stocks, (10.779). FOCL's Projected Growth (PEG Ratio) (8.100) is very high in comparison to the industry average of (2.016). Dividend Yield (0.000) settles around the average of (0.134) among similar stocks. P/S Ratio (1.919) is also within normal values, averaging (4.260).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FOCL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of minimally invasive medical devices for urological diseases
Industry MedicalDistributors
Advertisement